Loading company
Northwest Biotherapeutics Inc.
NWBO · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
NWBO · OTC
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $883K | $200K | +341.50% |
| Profit | -$28.8M | -$26.8M | -7.20% |
| Profit per share | -$0.02 | -$0.02 | 0.00% |
| Free Cash Flow | -$8.8M | -$14.1M | +37.49% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Northwest Biotherapeutics Inc. has no earnings call transcript available.
The quote and the company description come from Northwest Biotherapeutics Inc.’s Item 2.02 8-K filed August 9, 2013; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.